Novartis' Avidity Deal: Growth Accretive, Multiple Gated By Execution

Novartis acquires Avidity Biosciences for $12B to boost growth and rare disease pipeline. Explore impacts, risks, and outlook ...

Novartis to buy Avidity Biosciences in $12B deal to boost rare disease pipeline

Novartis (NYSE:NVS) (OTCPK:NVSEF) (TSX:NVS:CA) said Sunday it will acquire California-based Avidity Biosciences (NASDAQ:RNA) ...

Avidity stock surges on $12B Novartis deal

Avidity Biosciences (NASDAQ:RNA) shares surged as much as 45% in premarket trading on Monday after Novartis (NYSE:NVS) agreed to buy the biotechnology company in a deal valued at $12 billion. Novartis ...
Seeking Alpha

Biohaven: Cash Hog Awaits FDA Decision On SCA

Biohaven's market cap has dropped significantly from $3.9 billion to $1.42 billion, making its valuation more reasonable. Despite a broad pipeline, Biohaven still generates no revenues, which, with ...